GVGuillermo Villa

Guillermo Villa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillermo Villa has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

    by Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström

    Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known about the efficacy of PCSK9 inhibition in clinical practice. This study aimed to describe the change in LDL-C levels over time and LDL-C goal achievement in patients with/without atherosclerotic cardiovascular disease (ASCVD), who were prescribed evolocumab in clinical practice, and to describe adherence to and persistence with treatment. Methods: Patients in Sweden with at least one evolocumab prescription filled between July 2015 and May 2020 were included. Medical history and lipid-lowering therapy (LLT) were sourced from national registries. LDL-C levels before and after treatment initiation were assessed using medical records. Persistence with and adherence to evolocumab and oral LLT were assessed up to 12 months after treatment initiation using the refill-gap method and proportion of days covered, respectively. Results: Of the 2,360 patients with at least one prescription for evolocumab, 2,341 were included; 1,858 had ASCVD. Persistence with (76%) and adherence to (86%) evolocumab were high throughout the 12 months following initiation. Mean LDL-C levels decreased by 53% (95% confidence interval [CI]: 51–55%) in patients adherent to evolocumab (n = 567) and 59% (95% CI: 55–63%) in patients adherent to evolocumab and oral LLT (n = 186). Similar reductions in LDL-C were observed in patients with/without ASCVD. Reduced LDL-C levels remained stable during follow-up. Amongst patients adherent to evolocumab and those adherent to evolocumab and oral LLT, 23 and 55% achieved the LDL-C goal of <1.4 mmol/L, respectively. Conclusions: The evolocumab LDL-C-lowering effect observed in clinical trials was confirmed in clinical practice in Sweden, particularly in patients also treated with oral LLT. During follow-up, adherence to and persistence with evolocumab were high, with stable reduced levels of LDL-C during observation.


  • Open Access

    Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study

    by Maria K. Svensson, Francesc Sorio Vilela, Margrét Leósdóttir, Jonas Banefelt, Maria Lindh, Alexander Rieem Dun, Anna Norhammar, Guillermo Villa

    Background: Oral lipid-lowering treatment (LLT) is the standard of care for patients with cardiovascular disease (CVD). However, insufficient treatment intensity and poor adherence can lead to suboptimal treatment benefit, rendering patients at increased risk of CVD. Aims: The objective of this study was to evaluate trends in LLT intensity and adherence in Sweden over time, and their association with major adverse cardiovascular events (MACE) after recent myocardial infarction (MI), and also to assess the impact of transition from secondary to primary care on intensity and adherence. Methods and results: This retrospective observational cohort study used data from Swedish nationwide patient registers and included patients on LLT after an MI in the years 2010–2016 (n = 50,298; mean age, 68 years; 69% men). LLT intensity was evaluated over time (overall, for 2010–2013 and for 2014–2016) as the proportion of patients prescribed low-, moderate-, and high-intensity LLT. Adherence was assessed as the proportion of days covered. A combined measure of intensity and adherence was also considered. Differences in treatment patterns and MACE were assessed. Initiation of high-intensity LLT increased over the two time periods studied (2010–2013, 32%; 2014–2016, 91%). Adherence varied by LLT intensity and was highest in patients receiving high-intensity LLT (>80%), especially during the first time period. Little change in treatment intensity or the combined measure of intensity and adherence was observed after transition to primary care. There was a significant association between the combined measure of intensity and adherence and MACE reduction (hazard ratio [95% confidence interval] per 10% increase in the combined measure: 0.84 [0.82–0.86]; P < 0.01). Conclusion: The proportion of post-MI patients with high LLT intensity and adherence has increased in recent years, with little change after transfer from specialist to primary care. The combination of LLT intensity and adherence is important for preventing future cardiovascular events.


  • COMPARISON OF ACHIEVING 2019 ESC/EAS VERSUS 2018 ACC/AHA LDL-C GOALS FOR PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A CARDIOVASCULAR RISK SIMULATION FROM THE DA VINCI STUDY

    by Kosh R. Ray, Sarah Bray, Alberico L. Catapano, Neil Poulter, Antonio J. Vallejo-Vaz, Julia Brandts, Guillermo Villa

  • Open Access

    Migraine day frequency in migraine prevention: longitudinal modelling approaches

    by Gian Luca Di Tanna, Joshua K. Porter, Richard B. Lipton, Alan Brennan, Stephen Palmer, Anthony J. Hatswell, Sandhya Sapra, Guillermo Villa

    Health economic models are critical tools to inform reimbursement agencies on health care interventions. Many clinical trials report outcomes using the frequency of an event over a set period of time, for example, the primary efficacy outcome in most clinical trials of migraine prevention is mean change in the frequency of migraine days (MDs) per 28 days (monthly MDs [MMD]) relative to baseline for active treatment versus placebo. Using these cohort-level endpoints in economic models, accounting for variation among patients is challenging. In this analysis, parametric models of change in MMD for migraine preventives were assessed using data from erenumab clinical studies. MMD observations from the double-blind phases of two studies of erenumab were used: one in episodic migraine (EM) (NCT02456740) and one in chronic migraine (CM) (NCT02066415). For each trial, two longitudinal regression models were fitted: negative binomial and beta binomial. For a thorough comparison we also present the fitting from the standard multilevel Poisson and the zero inflated negative binomial. Using the erenumab study data, both the negative binomial and beta-binomial models provided unbiased estimates relative to observed trial data with well-fitting distribution at various time points. This proposed methodology, which has not been previously applied in migraine, has shown that these models may be suitable for estimating MMD frequency. Modelling MMD using negative binomial and beta-binomial distributions can be advantageous because these models can capture intra- and inter-patient variability so that trial observations can be modelled parametrically for the purposes of economic evaluation of migraine prevention. Such models have implications for use in a wide range of disease areas when assessing repeated measured utility values.


  • Novel Biologics Versus Conventional Preventive Therapies In Migraine: A Framework for Economic Evaluation

    by Rb Lipton, A Brennan, S Palmer, Jp Jansen, Aj Hatswell, Jk Porter, Gl Di Tanna, G Villa, N Shah, S Sapra


  • Open Access

    Desarrollo de productos avanzados para la misión SEOSAT/Ingenio

    by N. Sabater, A. Ruiz-Verdú, J. Delegido, R. Fernández-Beltrán, P. Latorre-Carmona, F. Pla, M. González-Audícana, J. Álvarez-Mozos, I. Sola, G. Villa, et al.

    SEOSAT/Ingenio is the future Spanish Earth Observation high spatial resolution mission in the optical domain. While Level 1 products, at-sensor geo-referenced radiances, are in an advanced phase of development under the framework of an industrial contractor, Level 2 products must be developed by the users. This fact limits the use of the satellite images only to the scientific community, restricting their use in other applications. The need to alleviate this limitation motivated this work, developed under the framework of a coordinate project, which aimed at offering a list of Level2 products to the Ingenio/SEOSAT user community. In this paper, we present the different methodologies developed to produce the proposed Level2 products, from surface reflectance at nominal sensor spatial resolution to images with higher spatial resolution or the possibility to create spatial and temporal mosaics. On the one side, for the surface reflectance product, we proposed an atmospheric correction algorithm based on using the spatial information, linked to a cloud screening algorithm and including morphological and topographic shadow corrections. On the other side, to enhance the image spatial resolution, we applied different fusion techniques using the multispectral and the panchromatic band, as well as some of the so-called “super-resolution” techniques. Finally, we provided different tools to develop spatial mosaics and temporal composites, directed to users interested on the exploitation of the Ingenio/ SEOSAT images.

  • Open Access

    Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain

    by Guillermo Villa, Emilio Sánchez-Álvarez, Jesús Cuervo, Lucía Fernández-Ortiz, Pablo Rebollo, Francisco Ortega

    A cost-effectiveness analysis of timely dialysis referral after renal transplant failure was undertaken from the perspective of the Public Administration. The current Spanish situation, where all the patients undergoing graft function loss are referred back to dialysis in a late manner, was compared to an ideal scenario where all the patients are timely referred.


  • Open Access

    Validation of a computer-adaptive test to evaluate generic health-related quality of life

    by Pablo Rebollo, Ignacio Castejon, Jesus Cuervo, Guillermo Villa, Eduardo Garcia-Cueto, Helena Diaz-Cuervo, Pilar C Zardain, Jose Muniz, Jordi Alonso, Spanish CAT-HEALTH Research group

    Health Related Quality of Life (HRQoL) is a relevant variable in the evaluation of health outcomes. Questionnaires based on Classical Test Theory typically require a large number of items to evaluate HRQoL. Computer Adaptive Testing (CAT) can be used to reduce tests length while maintaining and, in some cases, improving accuracy. This study aimed at validating a CAT based on Item Response Theory (IRT) for evaluation of generic HRQoL: the CAT-Health instrument. Cross-sectional study of subjects aged over 18 attending Primary Care Centres for any reason. CAT-Health was administered along with the SF-12 Health Survey. Age, gender and a checklist of chronic conditions were also collected. CAT-Health was evaluated considering: 1) feasibility: completion time and test length; 2) content range coverage, Item Exposure Rate (IER) and test precision; and 3) construct validity: differences in the CAT-Health scores according to clinical variables and correlations between both questionnaires. 396 subjects answered CAT-Health and SF-12, 67.2% females, mean age (SD) 48.6 (17.7) years. 36.9% did not report any chronic condition. Median completion time for CAT-Health was 81 seconds (IQ range = 59-118) and it increased with age (p < 0.001). The median number of items administered was 8 (IQ range = 6-10). Neither ceiling nor floor effects were found for the score. None of the items in the pool had an IER of 100% and it was over 5% for 27.1% of the items. Test Information Function (TIF) peaked between levels -1 and 0 of HRQoL. Statistically significant differences were observed in the CAT-Health scores according to the number and type of conditions. Although domain-specific CATs exist for various areas of HRQoL, CAT-Health is one of the first IRT-based CATs designed to evaluate generic HRQoL and it has proven feasible, valid and efficient, when administered to a broad sample of individuals attending primary care settings.